Unknown

Dataset Information

0

Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.


ABSTRACT: Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-small-cell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor-infiltrating lymphocytes (TILs) and CD8+ TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1-49%, and ?50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3+/CD8+ TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3+/CD8+ TIL proportions and the intensity of CD8+ TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1-49%, and ?50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3+/CD8+ TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8+ TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.

SUBMITTER: Batur S 

PROVIDER: S-EPMC7416171 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7271386 | BioStudies
1000-01-01 | S-EPMC5035793 | BioStudies
2019-01-01 | S-EPMC6322302 | BioStudies
2018-01-01 | S-EPMC5884516 | BioStudies
1000-01-01 | S-EPMC4747372 | BioStudies
2018-01-01 | S-EPMC5839005 | BioStudies
1000-01-01 | S-EPMC5198965 | BioStudies
2020-01-01 | S-EPMC7157900 | BioStudies
2020-01-01 | S-EPMC7481638 | BioStudies
2019-01-01 | S-EPMC6525886 | BioStudies